Table 1.
Characteristics of patients, eyes and treatment
| Patient | Eye | Age | Sex | Laterality | RE | IC | Prior Tx |
No. initial OAC infusions |
Cumulative drug dose (mg) for initial OAC* |
Latency (mos) |
No. 2nd course infusions |
Cumulative drug dose (mg) for 2nd course OAC* |
3rd, 4th, 5th line tx |
# addtl OAC courses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | OD | 11.0 | F | B | VA | D | Yes | 3 | M5.5, T0.9, C25 | 7.0 | 3 | M8, C60, T0.8 | EBR | |
| 2 | OD | 6.3 | F | U | VB | D | No | 4 | M11 | 10.2 | 1 | M4,T0.3 | enu | |
| 3 | OS | 197.9 | F | B | VB | E | Yes | 3 | M21, T1.2, C120 | 15.2 | 2 | M8, T0.5, C110 | None | |
| 4 | OD | 3.1 | F | B | IIIA | B | No | 1 | M2 | 20.0 | 3 | M12, T.9 | OAC | 1 |
| 5 | OS | 14.0 | F | B | VB | D | Yes | 3 | M8, T0.3 | 7.0 | 2 | M11, T.9, C70 | OAC, enu | 1 |
| 6 | OD | 24.9 | M | U | VB | D | No | 3 | M15 | 4.3 | 3 | C95 | enu | |
| 7 | OS | 32.5 | M | B | VB | D | Yes | 3 | M12, T0.9 | 13.3 | 1 | M6, T0.4, C30 | Ivit, enu | |
| 8 | OD | 24.5 | M | B | IVA | B | Yes | 1 | M4 | 4.9 | 2 | M9, T0.4 | OAC | 1 |
| 9 | OS | 14.0 | M | B | VB | D | Yes | 1 | M3 | 14.7 | 4 | M25, T1.6 | OAC, enu | 1 |
| 10 | OD | 15.6 | F | B | VB | D | Yes | 3 | M9.5 | 3.3 | 1 | C30 | OAC | 1 |
| 11 | OD | 5.2 | M | U | VA | D | No | 3 | M10, T1 | 3.0 | 1 | M4 | None | |
| 12 | OD | 9.9 | M | U | IVA | C | Yes | 3 | M8, T2, C40 | 3.7 | 2 | M10, T3, C100 | None | |
| 13 | OS | 28.6 | M | B | VB | E | No | 6 | M37.5, T2.5, C250 | 14.5 | 1 | M7.5, T0.5, C50 | plq, Ivit | |
| 14 | OS | 6.9 | M | B | IIA | B | Yes | 3 | M8 | 38.7 | 1 | M7.5, T.5 | OAC | 2 |
| 15 | OD | 7.9 | M | B | IB | B | Yes | 1 | M2.5 | 3.1 | 1 | M3, T.2 | None | |
| 16 | OD | 7.2 | F | B | VB | D | Yes | 3 | M7.5, T.3 | 13.5 | 1 | M4, T.5 | OAC, Ivit | 2 |
| 17 | OD | 25.3 | M | B | VB | D | Yes | 5 | M29, T1.3 | 4.6 | 1 | T.4, C40 | OAC | 1 |
| 18 | OD | 8.9 | F | B | VA | D | No | 3 | M4, T.5, C80 | 3.5 | 2 | M9, T2, C110 | None | |
| 19 | OD | 4.4 | F | B | VA | E | Yes | 3 | M6, T.9, C30 | 2.8 | 1 | M3, T.3, C30 | OAC, Ivit | 1 |
| 20 | OS | 15.7 | M | U | VB | D | No | 4 | M16, T1.3, C30 | 2.8 | 2 | M10, T1.5, C80 | OAC, plq, Ivit |
2 |
| 21 | OD | 33.3 | M | U | VB | D | No | 3 | M15, T..4 | 3.7 | 3 | M15, T1.2 | enu | |
| 22 | OD | 10.6 | F | B | IB | B | No | 1 | M3, T.3 | 4.2 | 1 | M3, T.3 | OAC | |
| OS | 6.7 | B | VB | D | No | 2 | T.8, C60 | 3.0 | 1 | T.3, C30 | None | 2 | ||
| 23 | OD | 63.5 | F | U | VB | D | No | 5 | M28, T1.8, C30 | 7.5 | 2 | M15, T2.5, C30 | OAC, plq | 2 |
| 24 | OD | 8.6 | M | B | VB | D | No | 6 | M21, T1.6, C30 | 3.0 | 2 | M9, T.7, C55 | Ivit | |
| 25 | OD | 53.0 | F | B | IIA | D | Yes | 3 | M15, T.8, C60 | 4.4 | 1 | M6, T.5, C50 | OAC, Ivit | 1 |
| 26 | OS | 10.0 | M | U | VB | D | No | 3 | C150 | 3.5 | 2 | M8, T4 | None | |
| 27 | OS | 96.6 | M | B | VB | D | Yes | 4 | M13 | 8.4 | 2 | M8, T.3 | enu | |
| 28 | OS | 57.3 | F | U | VB | D | No | 4 | M19, T4 | 42.5 | 3 | M18, T.5, C100 | None | |
RE= Reese-Ellsworth at diganosis, IC= International Classification at diagnosis, Tx = treatment, OAC= ophthalmic artery chemosurgery, addtl = additional, OD= right eye, OS= left eye, F = female, M= male, B= bilateral, U= unilateral, EBR= external beam radiation, enu= enucleation, Ivit= intraivtreal melphalan, plq= plaque brachytherapy, *M= melphalan, T= topotecan, C= carboplatin and number refers to dose of drug in mg.